Artículo
Ewing Sarcoma Meets Epigenetics, Immunology and Nanomedicine: Moving Forward into Novel Therapeutic Strategies
Autor/es | Sánchez Molina, Sara
Figuerola Bou, Elisabet Sánchez Margalet, Víctor Cruz Merino, Luis de la Mora, Jaume Álava Casado, Enrique de García-Domínguez, Daniel J. Hontecillas Prieto, Lourdes |
Departamento | Universidad de Sevilla. Departamento de Bioquímica Médica y Biología Molecular e Inmunología Universidad de Sevilla. Departamento de Medicina Universidad de Sevilla. Departamento de Citología e Histología Normal y Patológica |
Fecha de publicación | 2022-11-07 |
Fecha de depósito | 2023-04-20 |
Publicado en |
|
Resumen | Ewing Sarcoma (EWS) is an aggressive bone and soft tissue tumor that mainly affects children, adolescents, and young adults. The standard therapy, including chemotherapy, surgery, and radiotherapy, has substantially improved ... Ewing Sarcoma (EWS) is an aggressive bone and soft tissue tumor that mainly affects children, adolescents, and young adults. The standard therapy, including chemotherapy, surgery, and radiotherapy, has substantially improved the survival of EWS patients with localized disease. Unfortunately, this multimodal treatment remains elusive in clinics for those patients with recurrent or metastatic disease who have an unfavorable prognosis. Consistently, there is an urgent need to find new strategies for patients that fail to respond to standard therapies. In this regard, in the last decade, treatments targeting epigenetic dependencies in tumor cells and the immune system have emerged into the clinical scenario. Additionally, recent advances in nanomedicine provide novel delivery drug systems, which may address challenges such as side effects and toxicity. Therefore, therapeutic strategies stemming from epigenetics, immunology, and nanomedicine yield promising alternatives for treating these patients. In this review, we highlight the most relevant EWS preclinical and clinical studies in epigenetics, immunotherapy, and nanotherapy conducted in the last five years. |
Agencias financiadoras | Junta de Andalucía. Consejeria de Salud y Familias FIS-FEDER |
Identificador del proyecto | RH-0047-2021
PI2000003 |
Cita | Sánchez Molina, S., Figuerola Bou, E., Sánchez Margalet, V., Cruz Merino, L.d.l., Mora, J., Álava Casado, E.d.,...,Hontecillas-Prieto, L. (2022). Ewing Sarcoma Meets Epigenetics, Immunology and Nanomedicine: Moving Forward into Novel Therapeutic Strategies. Cancers, 14 (21), 5473. https://doi.org/doi.org/10.3390/cancers14215473. |
Ficheros | Tamaño | Formato | Ver | Descripción |
---|---|---|---|---|
Ewing Sarcoma Meets Epigenetics, ... | 2.276Mb | [PDF] | Ver/ | |